Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug

Acadia Pharmaceuticals

26/06/2026 12:47

** Shares of Acadia Pharmaceuticals ACAD.O rise 14% to $27 premarket
** Co says that Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion following a re-examination procedure on its marketing application for daybu for the treatment of neurobehavioral symptoms of Rett syndrome, following its recent CHMP oral explanation
** Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops
** RBC Capital Market says "CHMP cited that while the effect sizes were small, the totality of the data was clinically relevant, resulting in the positive outcome"
** Brokerage adds the concerns had also been raised during the U.S. FDA's review of the drug, which nevertheless approved it, but expectations for a reversal in Europe were low
** RBC says "today's surprise CHMP reversal should further increase the fundamental valuation floor" for ACAD
** Following the CHMP recommendation, the European Commission will review the opinion and is expected to issue a final decision in the coming months
** As of last close, stock down 11.2% YTD

 (Reporting by Siddhi Mahatole)
 ((siddhi.mahatole@thomsonreuters.com))